Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas.
JAMA Netw Open. 2022 Oct 3;5(10):e2234221. doi: 10.1001/jamanetworkopen.2022.34221.
Alcohol drinking and obesity are associated with an increased risk of cirrhosis and hepatocellular carcinoma (HCC), but the risk is not uniform among people with these risk factors. Genetic variants, such as I148M in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene, may play an important role in modulating cirrhosis and HCC risk.
To investigate the joint associations of the PNPLA3 I148M variant, alcohol intake, and obesity with the risk of cirrhosis, HCC, and liver disease-related mortality.
DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study analyzed 414 209 participants enrolled in the UK Biobank study from March 2006 to December 2010. Participants had no previous diagnosis of cirrhosis and HCC and were followed up through March 2021.
Self-reported alcohol intake (nonexcessive vs excessive), obesity (body mass index ≥30 [calculated as weight in kilograms divided by height in meters squared]), and PNPLA3 I148M variant status (noncarrier, heterozygous carrier, or homozygous carrier) from initial assessment.
The primary outcomes were incident cirrhosis and HCC cases and liver disease-related death ascertained from inpatient hospitalization records and death registry. The risks were calculated by Cox proportional hazards regression models.
A total of 414 209 participants (mean [SD] age, 56.3 [8.09] years; 218 567 women [52.8%]; 389 452 White race and ethnicity [94.0%]) were included. Of these participants, 2398 participants (0.6%) developed cirrhosis (5.07 [95% CI, 4.87-5.28] cases per 100 person-years), 323 (0.1%) developed HCC (0.68 [95% CI, 0.61-0.76] cases per 100 person-years), and 878 (0.2%) died from a liver disease-related cause (1.76 [95% CI, 1.64-1.88] cases per 100 person-years) during a median follow-up of 10.9 years. Synergistic interactions between the PNPLA3 I148M variant, obesity, and alcohol intake were associated with the risk of cirrhosis, HCC, and liver disease-related mortality. The risk of cirrhosis increased supramultiplicatively (adjusted hazard ratio [aHR], 17.52; 95% CI, 12.84-23.90) in individuals with obesity, with excessive drinking, and who were homozygous carriers compared with those with no obesity, with nonexcessive drinking, and who were noncarriers. Supramultiplicative associations between the 3 factors and risks of HCC were found in individuals with 3 risk factors (aHR, 30.13; 95% CI, 16.51-54.98) and liver disease-related mortality (aHR, 21.82; 95% CI, 13.78-34.56). The PNPLA3 I148M variant status significantly differentiated the risk of cirrhosis, HCC, and liver disease-related mortality in persons with excessive drinking and obesity.
This study found synergistic associations of the PNPLA3 I148M variant, excessive alcohol intake, and obesity with increased risk of cirrhosis, HCC, and liver disease-related death in the general population. The PNPLA3 I148M variant status may help refine the risk stratification for liver disease in persons with excessive drinking and obesity who may need early preventive measures.
饮酒和肥胖与肝硬化和肝细胞癌(HCC)的风险增加有关,但这些风险因素在人群中的分布并不均匀。基因变异,如 patatin-like 磷脂酶结构域包含蛋白 3(PNPLA3)基因中的 I148M,可能在调节肝硬化和 HCC 风险方面发挥重要作用。
研究 PNPLA3 I148M 变异、饮酒和肥胖与肝硬化、HCC 和与肝脏疾病相关的死亡率风险的联合关联。
设计、地点和参与者:这项前瞻性队列研究分析了 2010 年 3 月至 12 月期间参加英国生物银行研究的 414209 名参与者。参与者之前没有肝硬化和 HCC 的诊断,随访至 2021 年 3 月。
自我报告的饮酒量(非过量饮酒与过量饮酒)、肥胖(体重指数≥30[体重以千克为单位,身高以米为单位计算])和 PNPLA3 I148M 变异状态(非携带者、杂合子携带者或纯合子携带者)来自初步评估。
主要结果是通过住院记录和死亡登记确定的肝硬化和 HCC 新发病例和与肝脏疾病相关的死亡。通过 Cox 比例风险回归模型计算风险。
共纳入 414209 名参与者(平均[标准差]年龄,56.3[8.09]岁;218567 名女性[52.8%];389452 名白种人[94.0%])。其中,2398 名参与者(0.6%)发生肝硬化(每 100 人年 5.07[95%CI,4.87-5.28]例),323 名(0.1%)发生 HCC(每 100 人年 0.68[95%CI,0.61-0.76]例),878 名(0.2%)因与肝脏疾病相关的原因死亡(每 100 人年 1.76[95%CI,1.64-1.88]例)在中位随访 10.9 年后。PNPLA3 I148M 变异、肥胖和饮酒之间的协同相互作用与肝硬化、HCC 和与肝脏疾病相关的死亡率风险相关。与非肥胖、非过量饮酒且非携带者相比,肥胖、过量饮酒且纯合子携带者的肝硬化风险呈超倍数增加(调整后的危险比[aHR],17.52;95%CI,12.84-23.90)。在具有 3 种风险因素的个体中发现了 3 种因素之间的超倍关联与 HCC 风险(aHR,30.13;95%CI,16.51-54.98)和与肝脏疾病相关的死亡率(aHR,21.82;95%CI,13.78-34.56)。PNPLA3 I148M 变异状态显著区分了过量饮酒和肥胖个体的肝硬化、HCC 和与肝脏疾病相关的死亡率风险。
本研究发现 PNPLA3 I148M 变异、过量饮酒和肥胖与肝硬化、HCC 和与肝脏疾病相关的死亡率风险在一般人群中呈协同关联。PNPLA3 I148M 变异状态可能有助于在需要早期预防措施的过量饮酒和肥胖个体中对肝脏疾病进行风险分层。